Clinical characteristics of transplanted patients
| . | n . | % . | Patient reference ID . |
|---|---|---|---|
| Sex | |||
| Female | 11 | 42.3 | 1, 5, 7, 8, 11, 12, 20, 21, 22, 23, 25 |
| Male | 15 | 57.7 | 2, 3, 4, 6, 9, 10, 13, 14, 15, 16, 17, 18, 19, 24, 26 |
| UCB graft | |||
| Single unit | 24 | 92.3 | All except 19, 24 |
| Double units | 2 | 7.7 | 19, 24 |
| Hematologic malignancies | |||
| ALL | 11 | 42.3 | 1, 3, 8, 10, 13, 14, 15, 17, 18, 23, 26 |
| MDS | 8 | 30.8 | 5, 6, 7, 9, 12, 21, 22, 24 |
| AML | 4 | 15.4 | 2, 4, 20, 25 |
| Others | |||
| FHLH | 1 | 3.8 | 11 |
| Farber disease | 1 | 3.8 | 16 |
| Hurler syndrome | 1 | 3.8 | 19 |
| HLA disparity | |||
| 0 | 9 | 34.6 | 1, 4, 5, 6, 12, 14, 19, 23, 25 |
| 1 | 9 | 34.6 | 2, 3, 8, 10, 11, 16, 20, 21, 26 |
| 2 | 8 | 30.8 | 7, 9, 13, 15, 17, 18, 22, 24 |
| Outcome | |||
| Death | 8 | 30.8 | 1, 2, 7, 8, 12, 14, 19, 23 |
| Cytomegalovirus infection | 3 | 11.5 | 7, 9, 12 |
| Herpes virus infection (other) | 9 | 34.6 | 2, 9, 10, 11, 13, 15, 17, 21, 25 |
| Leukemic relapse | 8 | 34.8 | 2, 8, 12, 14, 20, 22, 23, 26 |
| Acute GVHD | 4 | 15.4 | 17, 18, 22, 24 |
| Chronic GVHD | 1 | 3.8 | 21 |
| Graft failure | 3 | 11.5 | 1, 6, 19 |
| . | n . | % . | Patient reference ID . |
|---|---|---|---|
| Sex | |||
| Female | 11 | 42.3 | 1, 5, 7, 8, 11, 12, 20, 21, 22, 23, 25 |
| Male | 15 | 57.7 | 2, 3, 4, 6, 9, 10, 13, 14, 15, 16, 17, 18, 19, 24, 26 |
| UCB graft | |||
| Single unit | 24 | 92.3 | All except 19, 24 |
| Double units | 2 | 7.7 | 19, 24 |
| Hematologic malignancies | |||
| ALL | 11 | 42.3 | 1, 3, 8, 10, 13, 14, 15, 17, 18, 23, 26 |
| MDS | 8 | 30.8 | 5, 6, 7, 9, 12, 21, 22, 24 |
| AML | 4 | 15.4 | 2, 4, 20, 25 |
| Others | |||
| FHLH | 1 | 3.8 | 11 |
| Farber disease | 1 | 3.8 | 16 |
| Hurler syndrome | 1 | 3.8 | 19 |
| HLA disparity | |||
| 0 | 9 | 34.6 | 1, 4, 5, 6, 12, 14, 19, 23, 25 |
| 1 | 9 | 34.6 | 2, 3, 8, 10, 11, 16, 20, 21, 26 |
| 2 | 8 | 30.8 | 7, 9, 13, 15, 17, 18, 22, 24 |
| Outcome | |||
| Death | 8 | 30.8 | 1, 2, 7, 8, 12, 14, 19, 23 |
| Cytomegalovirus infection | 3 | 11.5 | 7, 9, 12 |
| Herpes virus infection (other) | 9 | 34.6 | 2, 9, 10, 11, 13, 15, 17, 21, 25 |
| Leukemic relapse | 8 | 34.8 | 2, 8, 12, 14, 20, 22, 23, 26 |
| Acute GVHD | 4 | 15.4 | 17, 18, 22, 24 |
| Chronic GVHD | 1 | 3.8 | 21 |
| Graft failure | 3 | 11.5 | 1, 6, 19 |
Conditioning regimen and GVHD prophylaxis are as described in “Methods.” Twenty-three (88.5%) of 26 subjects underwent transplantations to treat persistent malignant disease. The primary cause of posttransplantation mortality was leukemic relapse (n = 5). The frequency of leukemic relapse was calculated among subjects who had hematologic malignancies (n = 23). Subjects lost to follow-up (n = 2) were not included in the analysis.
ALL indicates acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; and FHLH, familial hemophagocytic lymphohistiocytosis.